Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy
04:35pm, Wednesday, 21'st May 2025
Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitiv
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
06:15am, Wednesday, 21'st May 2025
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosi
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
03:24pm, Tuesday, 20'th May 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
10:16am, Tuesday, 20'th May 2025
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innov
Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data
03:15pm, Monday, 19'th May 2025
Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe's telehealt
Regeneron Buys 23andMe in Bankruptcy Auction
01:05pm, Monday, 19'th May 2025
Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
12:39pm, Monday, 19'th May 2025
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
11:51am, Monday, 19'th May 2025
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
10:35am, Monday, 19'th May 2025
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.
Cramer's Stop Trading: Regeneron
10:34am, Monday, 19'th May 2025
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
10:14am, Monday, 19'th May 2025
Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health
Regeneron to buy 23andMe out of bankruptcy for $256m
09:52am, Monday, 19'th May 2025
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech firm filed for Chapter 11 bankruptcy. The deal includes 23a
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
08:40am, Monday, 19'th May 2025
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in th
